{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:22:37Z","timestamp":1790083357588,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.4158\/ep-2018-0365","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T15:47:07Z","timestamp":1541087227000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Disease Presentation and Remission Rate in Graves Disease Treated With Antithyroid Drugs: is Gender Really A Factor?"],"prefix":"10.1016","volume":"25","author":[{"given":"Talia","family":"Diker-Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tsvetov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2018-0365_bb0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves' disease","volume":"38","author":"Marin\u00f2","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP-2018-0365_bb0015","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0365_bb0020","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0365_bb0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/EJE-12-0651","article-title":"Genotypes in relation to phenotypic appearance and exposure to environmental factors in Graves' hyperthyroidism","volume":"167","author":"Vos","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0365_bb0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","article-title":"The spectrum of thyroid disease in a community: the Whickham survey","volume":"7","author":"Tunbridge","year":"1977","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2018-0365_bb0035","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","article-title":"Clinical practice. Graves' disease","volume":"358","author":"Brent","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0365_bb0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0365_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1373\/clinchem.2005.055194","article-title":"Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex","volume":"52","author":"Hoogendoorn","year":"2006","journal-title":"Clin Chem"},{"key":"10.4158\/EP-2018-0365_bb0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archopht.1993.01090020051022","article-title":"The initial clinical characteristics of Graves' orbitopathy vary with age and sex","volume":"111","author":"Kendler","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.4158\/EP-2018-0365_bb0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2018-0365_bb0060","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"10.4158\/EP-2018-0365_bb0065","doi-asserted-by":"crossref","first-page":"J109","DOI":"10.1016\/j.jaut.2011.10.003","article-title":"Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity","volume":"38","author":"Quintero","year":"2012","journal-title":"J Autoimmun"},{"key":"10.4158\/EP-2018-0365_bb0070","first-page":"1038","article-title":"Age and gender predict the outcome of treatment for Graves' hyperthyroidism","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0365_bb0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/eje.0.1470583","article-title":"Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease","volume":"147","author":"Nedreb\u00f8","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0365_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves' disease?","volume":"25","author":"Kimball","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/EP-2018-0365_bb0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/07435800.2014.914038","article-title":"Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy","volume":"40","author":"Kruljac","year":"2015","journal-title":"Endocr Res"},{"key":"10.4158\/EP-2018-0365_bb0090","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.25011\/cim.v32i3.6108","article-title":"Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil","volume":"32","author":"Cinemre","year":"2009","journal-title":"Clin Invest Med"},{"key":"10.4158\/EP-2018-0365_bb0095","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1542\/peds.2007-1535","article-title":"Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study","volume":"121","author":"Glaser","year":"2008","journal-title":"Pediatrics"},{"key":"10.4158\/EP-2018-0365_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1507\/endocrj.K06-069","article-title":"Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study","volume":"54","author":"Cappelli","year":"2007","journal-title":"Endocr J"},{"key":"10.4158\/EP-2018-0365_bb0105","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1089\/thy.2005.15.1047","article-title":"Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease","volume":"15","author":"Quadbeck","year":"2005","journal-title":"Thyroid"},{"key":"10.4158\/EP-2018-0365_bb0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","article-title":"Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study","volume":"49","author":"Benker","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2018-0365_bb0115","first-page":"305","article-title":"Outcome of Graves' thyrotoxicosis after antithyroid drug treatment","volume":"18","author":"Chiou","year":"1995","journal-title":"Chang Yi Xue Za Zhi"},{"key":"10.4158\/EP-2018-0365_bb0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1507\/endocrj1954.38.683","article-title":"Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism","volume":"38","author":"Tajiri","year":"1991","journal-title":"Endocrinol Jpn"},{"key":"10.4158\/EP-2018-0365_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM197707282970401","article-title":"Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease","volume":"297","author":"Greer","year":"1977","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2018-0365_bb0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ando.2015.08.004","article-title":"Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment","volume":"76","author":"Liu","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.4158\/EP-2018-0365_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-13-0811","article-title":"Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000\u20132010","volume":"170","author":"Mohlin","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0365_bb0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","article-title":"Predictors of long-term remission in patients with Graves' disease: a single center experience","volume":"44","author":"Anagnostis","year":"2013","journal-title":"Endocrine"},{"key":"10.4158\/EP-2018-0365_bb0145","first-page":"427","article-title":"Independent pretreatment predictors of Graves' disease outcome","volume":"49","author":"Dauk\u0161ien\u00eb","year":"2013","journal-title":"Medicina (Kaunas)"},{"key":"10.4158\/EP-2018-0365_bb0150","first-page":"690","article-title":"Remission of Grave's disease after oral anti-thyroid drug treatment","volume":"19","author":"Ishtiaq","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.4158\/EP-2018-0365_bb0155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/jc.2011-1944","article-title":"Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study","volume":"97","author":"L\u00e9ger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0365_bb0160","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4158\/EP161350.OR","article-title":"Gender influences the clinical presentation and long-term outcome of Graves disease","volume":"22","author":"Magri","year":"2016","journal-title":"Endocr Pract"},{"key":"10.4158\/EP-2018-0365_bb0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","volume":"16","author":"Carella","year":"2006","journal-title":"Thyroid"},{"key":"10.4158\/EP-2018-0365_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3803\/EnM.2016.31.2.213","article-title":"Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease","volume":"31","author":"Wiersinga","year":"2016","journal-title":"Endocrinol Metab"},{"key":"10.4158\/EP-2018-0365_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2006.12.004","article-title":"Gender as risk factor for autoimmune diseases","volume":"28","author":"Gleicher","year":"2007","journal-title":"J Autoimmun"},{"key":"10.4158\/EP-2018-0365_bb0180","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves' hyperthyroidism","volume":"153","author":"Abraham","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0365_bb0185","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-16-0938","article-title":"Management of endocrine disease: arguments for the prolonged use of antithyroid drugs in children with Graves' disease","volume":"177","author":"L\u00e9ger","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2018-0365_bb0190","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves' disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2018-0365_bb0195","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid drugs-the most common treatment for Graves' disease in the United States: a nationwide population-based study","volume":"26","author":"Brito","year":"2016","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20359425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20359425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:07:33Z","timestamp":1761516453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20359425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1530891X20359425"],"URL":"https:\/\/doi.org\/10.4158\/ep-2018-0365","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease Presentation and Remission Rate in Graves Disease Treated With Antithyroid Drugs: is Gender Really A Factor?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2018-0365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}